Literature DB >> 12444167

Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody.

Herbert P M Brok1, Marjan van Meurs, Erwin Blezer, Allen Schantz, David Peritt, George Treacy, Jon D Laman, Jan Bauer, Bert A 't Hart.   

Abstract

The experimental autoimmune encephalomyelitis (EAE) model in the common marmoset approximates recognized features of the human disease multiple sclerosis (MS) with regard to its clinical presentation as well as neuropathological and radiological aspects of the lesions in brain and spinal cord. IL-12 is a proinflammatory cytokine that is produced by APC and promotes differentiation of Th1 effector cells. IL-12 is produced in the developing lesions of patients with MS as well as in EAE-affected animals. Previously it was shown that interference in IL-12 pathways effectively prevents EAE in rodents. In this study we report that in vivo neutralization of IL-12p40 using a novel Ab has beneficial effects in the myelin-induced EAE model in common marmosets. The Ab was injected i.v. at 7-day intervals starting well after immunization (day 14) and was continued until the end of the study (day 86). Stable levels of the Ab were measured 3 days after each injection throughout the study period. During this period anti-Ab responses could not be detected. We demonstrate that anti-IL-12p40 treatment has a protective effect on the neurological dysfunction as well as on neuropathological changes normally observed in the brain and spinal cord of EAE-affected individuals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12444167     DOI: 10.4049/jimmunol.169.11.6554

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

Review 1.  Cytokine-based immunointervention in the treatment of autoimmune diseases.

Authors:  L Adorini
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

Review 2.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 3.  Monoclonal antibodies as disease modifying therapy in multiple sclerosis.

Authors:  Erin E Longbrake; Becky J Parks; Anne H Cross
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

4.  Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates.

Authors:  Lizette Visser; Marie-José Melief; Debby van Riel; Marjan van Meurs; Ella A Sick; Seiichi Inamura; Jeffrey J Bajramovic; Sandra Amor; Rogier Q Hintzen; Leonie A Boven; Bert A 't Hart; Jon D Laman
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

Review 5.  Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors:  Bharath Wootla; Jens O Watzlawik; Nikolaos Stavropoulos; Nathan J Wittenberg; Harika Dasari; Murtada A Abdelrahim; John R Henley; Sang-Hyun Oh; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Opin Biol Ther       Date:  2016-03-10       Impact factor: 4.388

6.  Advantages and Risks of Husbandry and Housing Changes to Improve Animal Wellbeing in a Breeding Colony of Common Marmosets (Callithrix jacchus).

Authors:  Jaco Bakker; Boudewijn Ouwerling; Peter J Heidt; Ivanela Kondova; Jan A M Langermans
Journal:  J Am Assoc Lab Anim Sci       Date:  2015-05       Impact factor: 1.232

Review 7.  IL12Rβ1: the cytokine receptor that we used to know.

Authors:  Richard T Robinson
Journal:  Cytokine       Date:  2014-12-13       Impact factor: 3.861

Review 8.  Ustekinumab: a new option in psoriasis therapy.

Authors:  Anna L Chien; James T Elder; Charles N Ellis
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

Review 9.  Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development.

Authors:  Yolanda S Kap; Jon D Laman; Bert A 't Hart
Journal:  J Neuroimmune Pharmacol       Date:  2009-10-14       Impact factor: 4.147

10.  Ustekinumab in the therapy of chronic plaque psoriasis.

Authors:  Jenna L O'Neill; Robert E Kalb
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.